Fragmented polymeric compositions and methods for their use

• US 8,357,378 B2
• Filed: 05/24/2011
• Issued: 01/22/2013
• Est. Priority Date: 08/27/1996
• Status: Expired due to Fees

• Current Assignee: Baxter Healthcare SA (Baxter International Inc.), Baxter International Inc.
• Original Assignee: Baxter Healthcare SA (Baxter International Inc.), Baxter International Inc.
• Inventors: Wallace, Donald G., Reich, Cary J., Shargill, Narinder S., Vega, Felix, Osawa, A. Edward
• Primary Examiner(s): CHANNAVAJJALA, LAKSHMI SARADA
• Application Number:
  US13/114,784
• Publication Number:
  US 20110223231A1
• Time in Patent Office: 609 Days
• Field of Search: None
• US Class Current: 424/400
• CPC Class Codes: A61L 2300/418 Agents promoting blood coagulation, blood-clotting agents, embolising agents
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 24/0015 Medicaments; Biocides
• CPC Class Codes: A61L 24/0031 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 27/52 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: Y10S 524/916 Hydrogel compositions

Abstract

Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient'"'"'s body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.

Claims

1. A medical delivery device consisting of:

a sterile syringe having an extrusion orifice; and

an amount of a resorbable fragmented partially hydrated cross-linked gelatin gel present in the syringe, wherein the gel has an equilibrium swell ranging from 400% to 1300%.

2. The device according to claim 1, wherein the gel has an equilibrium swell ranging from 500% to 1100%.

3. The device according to claim 2, wherein the gel biodegrades in a patient'"'"'s body in a time period ranging from 1 to 90 days.

4. The device according to claim 1, wherein the gel biodegrades in a patient'"'"'s body in time period ranging from 2 to 30 days.

5. The device according to claim 1, wherein the gel resorbs in a time period ranging from 14 to 60 days.

6. The device according to claim 1, wherein the diameter of the extrusion orifice is in the range from 0.01 mm to 5.0 mm.